Shelf Life for Accelerated Approvals; CRC Tall Tale; Survivorship: Who’s in Charge?

Shelf Life for Accelerated Approvals; CRC Tall Story; Survivorship: Who’s in Cost?

Laws launched by Rep. Frank Pallone (D-N.J.) would give the FDA authority to set an expiration date on accelerated approvals. (Regulatory Affairs Professionals Society)

Immune checkpoint inhibitors developed in China should overcome main obstacles to realize a market foothold in Western nations. (GlobalData)

Merck introduced that adjuvant pembrolizumab (Keytruda) considerably improved distant metastasis-free survival in melanoma within the part III, placebo-controlled KEYNOTE-716 trial.

Gilead Sciences introduced that the part III TROPiCS-02 trial met the first endpoint of improved progression-free survival with the antibody-drug conjugate sacituzumab govitecan (Trodelvy) in beforehand handled metastatic hormone receptor-positive breast most cancers.

The FDA has positioned a partial maintain on the NEON-2 medical trial of davoceticept-pembrolizumab mixture remedy for superior cancers following a deadly (grade 5) opposed occasion, Alpine Immune Sciences reported.

Taller adults could have the next danger of colorectal most cancers. (Johns Hopkins Drugs, Most cancers Epidemiology, Biomarkers & Prevention)

Ought to most cancers specialists or major care physicians and nurses take the lead in most cancers survivorship applications? (Oncology Enterprise Evaluation)

In a remark letter to CMS, the Group Oncology Alliance inspired the company to undertake a hard-line method to pharmacy profit supervisor charges.

Though charges of smoking have declined dramatically, charges amongst individuals in underserved communities stay twice the nationwide price. (Most cancers)

David Penberthy, MD, MBA, of Bon Secours Southside Regional Medical Heart in Petersburg, Virginia, has begun his time period as president of the Affiliation of Group Most cancers Facilities.

Frailty in older adults with most cancers considerably will increase the chance of postoperative mortality. (Annals of Surgical Oncology)

NuCana introduced discontinuation of the part III NuTide:121 trial of NUC-1031 (fosgemcitabine palabenamide) plus cisplatin after a deliberate futility evaluation confirmed the trial wouldn’t meet the first endpoint of general survival in superior biliary tract most cancers.

The decline in HPV-related cervical most cancers could have stalled and probably made a 180° flip. (UTHealth Houston, JNCI Most cancers Spectrum)

First canines, now ants can sniff out most cancers? (CNRS)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and in addition covers urology, dermatology, and ophthalmology. He joined MedPage At the moment in 2007. Comply with

Learn Extra

Leave a Comment

Your email address will not be published.